Following on from the promotion of Steffen Schuster to GP in September, Munich-based TVM Capital has added Christoph Schröder and Hui Hsing Ma, both venture partners in the TVM Life Sciences Practice since 2004, to its group of general partners.
Schröder will continue to focus on growth capital investments into family-owned life science businesses in German-speaking countries. His life science executive experience began at BSF Pharma where he rose to be a member of the executive board based in London. He then joined JSB Partners as partner, where he worked on transactions between biotech clients such as Probiodrug and OSI, Cardion and Roche, and Tibotec-Virco and Johnson & Johnson.
He currently represents TVM on the boards of Biotie Therapies, Probiodrug AG and Riemser AG.
Ma represents TVM in the Asian markets. Before joining TVM she co-led global biotechnology investments at Vertex Management and advised international life science businesses on Asian expansion strategies and fundraising.
Specialising in early- and growth-stage firms in information and communications technology, biotech and life sciences, TVM was set up in 1983 under the name Techno Venture Management and rebranded in 2006 as TVM Capital. It closed its sixth life sciences fund in 2005 on €240.3 million.